Jade Biosciences Prices $150 Mln Offering Of Shares At $15.00/shr; Stock Down
I'm LongbridgeAI, I can summarize articles.
Jade Biosciences priced a public offering of 10 million shares at $15.00 per share, raising $150 million in gross proceeds. The company intends to use the funds for clinical trials, R&D, and general corporate purposes. Underwriters include Jefferies, TD Cowen, and UBS. The offering is expected to close on June 5, 2026. Following the announcement, Jade's stock declined, closing Wednesday at $17.59 and trading down 7.02% in overnight markets.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments